| Name | Title | Contact Details |
|---|
Karuna Pharmaceuticals is a clinical-stage company targeting muscarinic cholinergic receptors for the treatment of psychosis and cognitive impairment across central nervous system (CNS) disorders.
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.
Satsuma Pharmaceuticals is focused on developing best-in-class products to address the unmet needs of migraine sufferers.
Alpha Genesis is a Yemassee, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.